Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine approved for emergency use with robust efficacy and immunogenicity...

Full description

Bibliographic Details
Main Authors: Nicolás MS Gálvez, Gaspar A Pacheco, Bárbara M Schultz, Felipe Melo-González, Jorge A Soto, Luisa F Duarte, Liliana A González, Daniela Rivera-Pérez, Mariana Ríos, Roslye V Berrios, Yaneisi Vázquez, Daniela Moreno-Tapia, Omar P Vallejos, Catalina A Andrade, Guillermo Hoppe-Elsholz, Carolina Iturriaga, Marcela Urzua, María S Navarrete, Álvaro Rojas, Rodrigo Fasce, Jorge Fernández, Judith Mora, Eugenio Ramírez, Aracelly Gaete-Argel, Mónica L Acevedo, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Daniela Weiskopf, Alba Grifoni, Alessandro Sette, Gang Zeng, Weining Meng, CoronaVacCL03 Study Group, José V González-Aramundiz, Marina Johnson, David Goldblatt, Pablo A González, Katia Abarca, Susan M Bueno, Alexis M Kalergis
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2022-10-01
Series:eLife
Subjects:
Online Access:https://elifesciences.org/articles/81477